Short- and long-term outcomes of HIV-infected patients admitted to the intensive care unit: Impact of antiretroviral therapy and immunovirological status

Annals of Intensive Care

Volumn 2, Issue 1, 2012, Pages

  Morquin, David ^a   Le Moing, Vincent ^a   Mura, Thibaut ^b,c   Makinson, Alain ^a   Klouche, Kada ^b   Jonquet, Olivier ^a,b   Reynes, Jacques ^a   Corne, Philippe ^a  

^a GUI DE CHAULIAC HOSPITAL   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c INSERM   (France)

Author keywords

Acquired immunodeficiency syndrome; Antiretroviral therapy; Critical care; Human immunodeficiency virus; Intensive care units; Mortality; Prognostic factors

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; HYPERTENSIVE FACTOR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENSIVE CARE UNIT; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIXED INFECTION; MORTALITY; OUTCOME ASSESSMENT; PANCREATITIS; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL; TOXIC EPIDERMAL NECROLYSIS; VIRUS LOAD;

EID: 84864252663     PISSN: None     EISSN: 21105820     Source Type: Journal    
DOI: 10.1186/2110-5820-2-25     Document Type: Article

References (29)

1. Wachter RM, Luce JM, Turner J, Volberding P, Hopewell PC: Intensive care of patients with the acquired immunodeficiency syndrome. Outcome and changing patterns of utilization. Am Rev Respir Dis 1986, 134:891-896.
2. Wachter RM, Russi MB, Bloch DA, Hopewell PC, Luce JM: Pneumocystis carinii pneumonia and respiratory failure in AIDS. Improved outcomes and increased use of intensive care units. Am Rev Respir Dis 1991, 143:251-256.
3. Bedos JP, Chastang C, Lucet JC, Kalo T, Gachot B, Wolff M: Early predictors of outcome for HIV patients with neurological failure. JAMA 1995, 273:35-40.
4. Thyrault M, Gachot B, Chastang C, Souweine B, Timsit JF, Bedos JP, Regnier B, Wolff M: Septic shock in patients with the acquired immunodeficiency syndrome. Intensive Care Med 1997, 23:1018-1023.
5. Nuesch R, Geigy N, Schaedler E, Battegay M: Effect of highly active antiretroviral therapy on hospitalization characteristics of HIV-infected patients. Eur J Clin Microbiol Infect Dis 2002, 21:684-687.
6. Morris A, Wachter RM, Luce J, Turner J, Huang L: Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003, 17:73-80.
7. Vincent B, Timsit JF, Auburtin M, Schortgen F, Bouadma L, Wolff M, Regnier B: Characteristics and outcomes of HIV-infected patients in the ICU: impact of the highly active antiretroviral treatment era. Intensive Care Med 2004, 30:859-866.
8. Powell K, Davis JL, Morris AM, Chi A, Bensley MR, Huang L: Survival for patients With HIV admitted to the ICU continues to improve in the current era of combination antiretroviral therapy. Chest 2009, 135:11-17.
9. Coquet I, Pavie J, Palmer P, Barbier F, Legriel S, Mayaux J, Molina JM, Schlemmer B, Azoulay E: Survival trends in critically ill HIV-infected patients in the highly active antiretroviral therapy era. Crit Care 2010, 14:R107.
10. Huang L, Quartin A, Jones D, Havlir DV: Intensive care of patients with HIV infection. N Engl J Med 2006, 355:173-181.
11. Nickas G, Wachter RM: Outcomes of intensive care for patients with human immunodeficiency virus infection. Arch Intern Med 2000, 160:541-547.
12. Afessa B, Green B: Clinical course, prognostic factors, and outcome prediction for HIV patients in the ICU. The PIP (pulmonary complications, ICU support, and prognostic factors in hospitalized patients with HIV) study. Chest 2000, 118:138-145.
13. Alves C, Nicolas JM, Miro JM, Torres A, Agusti C, Gonzalez J, Rano A, Benito N, Moreno A, Garcia F, et al: Reappraisal of the aetiology and prognostic factors of severe acute respiratory failure in HIV patients. Eur Respir J 2001, 17:87-93.
14. Vargas-Infante YA, Guerrero ML, Ruiz-Palacios GM, Soto-Ramirez LE, Del Rio C, Carranza J, Dominguez-Cherit G, Sierra-Madero JG: Improving outcome of human immunodeficiency virus-infected patients in a Mexican intensive care unit. Arch Med Res 2007, 38:827-833.
15. Morris A, Creasman J, Turner J, Luce JM, Wachter RM, Huang L: Intensive care of human immunodeficiency virus-infected patients during the era of highly active antiretroviral therapy. Am J Respir Crit Care Med 2002, 166:262-267.
16. Narasimhan M, Posner AJ, DePalo VA, Mayo PH, Rosen MJ: Intensive care in patients with HIV infection in the era of highly active antiretroviral therapy. Chest 2004, 125:1800-1804.
17. Croda J, Croda MG, Neves A, Dos Santos SD: Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit. Crit Care Med 2009, 37:1605-1611.
18. Miller RF, Allen E, Copas A, Singer M, Edwards SG: Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy. Thorax 2006, 61:716-721.
19. Dickson SJ, Batson S, Copas AJ, Edwards SG, Singer M, Miller RF: Survival of HIVinfected patients in the intensive care unit in the era of highly active antiretroviral therapy. Thorax 2007, 62:964-968.
20. Khouli H, Afrasiabi A, Shibli M, Hajal R, Barrett CR, Homel P: Outcome of critically ill human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. J Intensive Care Med 2005, 20:327-333.
21. van Lelyveld SF, Wind CM, Mudrikova T, van Leeuwen HJ, de Lange DW, Hoepelman AI: Short-and long-term outcome of HIV-infected patients admitted to the intensive care unit. Eur J Clin Microbiol Infect Dis 2011, 30:1085-1093.
22. Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, Pellegrin JL, Katlama C, Dabis F, Leport C: HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007, 46:72-77.
23. Grabar S, Le Moing V, Goujard C, Egger M, Leport C, Kazatchkine MD, Weiss L, Costagliola D: Response to highly active antiretroviral therapy at 6 months and longterm disease progression in HIV-1 infection. J Acquir Immune Defic Syndr 2005, 39:284-292.
24. Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L: Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000, 133:401-410.
25. Yeni: French experts group's recommendations for medical management of HIV infection: highlight and recommendations. 2008.
26. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Gunthard HF, Hammer SM, Hirsch MS, et al: Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010, 304:321-333.
27. Casalino E, Wolff M, Ravaud P, Choquet C, Bruneel F, Regnier B: Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit. AIDS 2004, 18:1429-1433.
28. Morris A, Masur H, Huang L: Current issues in critical care of the human immunodeficiency virus-infected patient. Crit Care Med 2006, 34:42-49.
29. Zolopa AAJ, Komarow L, et al: Immediate versus deferred ART in the setting of acute AIDS-related OI: final results of a randomized strategy trial: ACTG A5164. Boston, MA: 15th CROI; 2008. Abstract 142